Descovy for PrEP, but not for women says FDA committee. Huh?

News broke on August 7, 2019, that the committee that makes recommendations at the FDA for new drug indication approvals recommended Gilead’s Descovy for PrEP—to prevent HIV transmissions to those that are recently tested and assumed negative for HIV.

However the recommendation failed to include any group or population outside of the specific populations that were included in Gilead’s clinical trials—men who have sex with men and transgender individuals.

This means that cisgender women are not included in the proposed approval. Is this okay?

Are we about to leave out cisgender women in the new PrEP indication to prevent HIV? #WAXoh! news presented by @datingpositives #spox pic.twitter.com/EhurTzWKly

— Josh Robbins (@imstillJosh) August 13, 2019